Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 68

recruiting
3 987
countries
28
conditions
2 109

820 trials match your criteria

Dry age-related macular degeneration

Not recruiting

Study on the Safety of Avacincaptad Pegol for Patients with Geographic Atrophy Who Completed a Previous Study

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avacincaptad Pegol

Colon cancer

Not recruiting

Comparison of drug combinations containing irinotecan, oxaliplatin, fluorouracil and folinic acid for treatment of high-risk stage III colon cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil

Plasma cell myeloma

Not recruiting

Study on Iberdomide for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem Cell Transplantation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iberdomide

Bronchopulmonary dysplasia

Not recruiting

Study on Mecasermin Rinfabate for Preventing Chronic Lung Disease in Extremely Premature Babies

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Mecasermin Rinfabate

Plasma cell myeloma

Not recruiting

Study Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone

Renal cell carcinoma

Not recruiting

Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Nasopharyngeal cancer

Not recruiting

Study of Pembrolizumab and Olaparib for Adults with Recurrent or Metastatic, Platinum-Resistant Nasopharyngeal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Elexacaftor

Pemphigoid

Not recruiting

Study on Long-term Safety and Effects of Efgartigimod PH20 SC for Adults with Bullous Pemphigoid

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa

Acute lymphocytic leukaemia

Not recruiting

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase

Neuroendocrine carcinoma metastatic

Not recruiting

Study of durvalumab, carboplatin and etoposide combination therapy for patients with metastatic large-cell neuroendocrine lung cancer who have not received previous treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Asthma

Not recruiting

Study on Reducing Asthma Medication with Tezepelumab in Patients Aged 12 to 80 with Severe Asthma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.